Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2

Status

Completed 31Active not recruiting 16Recruiting 14Terminated 11Withdrawn 5Not yet recruiting 2Suspended 1Enrolling by invitation 1

Sponsor Class

OTHER 3NIH 1INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Melanoma 17Carcinoma, Non-Small-Cell Lung 13Squamous Cell Carcinoma of Head and Neck 7Lung Neoplasms 5Colorectal Neoplasms 5Neoplasm Metastasis 4Head and Neck Neoplasms 4Neoplasms 3Multiple Myeloma 3Lymphoma 3Leukemia, Myeloid, Acute 3Carcinoma, Renal Cell 3Uterine Cervical Neoplasms 2Sarcoma 2Myelodysplastic Syndromes 2Lymphoma, B-Cell 2Hematologic Neoplasms 2Esophageal Neoplasms 2Central Nervous System Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Hepatocellular 2Adenocarcinoma 2Xeroderma Pigmentosum 1Vulvar Neoplasms 1Vaginal Neoplasms 1Uveal Melanoma 1Turcot syndrome 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Resectable Non-Small Cell Lung Cancer 1

Interventions

Oxaliplatin 20Fluorouracil 20Leucovorin 19Bevacizumab 16Cetuximab 13Irinotecan 12Capecitabine 8regorafenib 5Radiotherapy 5Nivolumab 5Drug Therapy 5aflibercept 4Radiosurgery 4Neoadjuvant Therapy 4Magnetic Resonance Spectroscopy 4Chemotherapy, Adjuvant 4Biopsy 4pembrolizumab 3durvalumab 3atezolizumab 3Specimen Handling 3Folfox protocol 3Cyclophosphamide 3trifluridine tipiracil drug combination 2tremelimumab 2tislelizumab 2poly(I).poly(c12,U) 2futuximab 2fludarabine 2avelumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Withdrawn × Colorectal Neoplasms × Nivolumab × Clear all
NCT06410534 2025-09-11

A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Withdrawn
Gastrointestinal

Colorectal Neoplasms

NCT03879811 2025-05-15

Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Withdrawn
Gastrointestinal

Colorectal Neoplasms

NCT03169777 2025-02-21

QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC

ImmunityBio, Inc.

Phase 1/2 Withdrawn
Gastrointestinal

Colorectal Neoplasms

NCT04430985 2021-10-27

IMMUNOX

Herlev Hospital

Phase 2 Withdrawn
Gastrointestinal

Colorectal Neoplasms

NCT03576963 2021-04-05

Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer

University of Southern California

Phase 1/2 Withdrawn
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡